Spyre Therapeutics, Inc.
SYRE
$28.40
-$0.26-0.91%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -100.00% |
| Cost of Revenue | 21.58% | 40.58% | 81.71% | 125.73% | 177.09% |
| Gross Profit | -21.58% | -40.58% | -83.06% | -128.53% | -182.75% |
| SG&A Expenses | -5.97% | -3.96% | 6.66% | 32.87% | 92.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.65% | 28.47% | 45.56% | 76.01% | 116.56% |
| Operating Income | -14.65% | -28.47% | -46.24% | -77.33% | -119.13% |
| Income Before Tax | 30.66% | -11.22% | 42.63% | 38.62% | 27.03% |
| Income Tax Expenses | -128.00% | -88.57% | -90.48% | 296.15% | 316.67% |
| Earnings from Continuing Operations | 30.68% | -11.20% | 42.64% | 38.60% | 27.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 30.68% | -11.20% | 42.64% | 38.60% | 27.01% |
| EBIT | -14.65% | -28.47% | -46.24% | -77.33% | -119.13% |
| EBITDA | 68.60% | 32.61% | -9.72% | -77.83% | -121.31% |
| EPS Basic | -112.99% | -322.19% | 96.05% | 96.12% | 112.16% |
| Normalized Basic EPS | 64.09% | 79.55% | 89.53% | 89.36% | 82.13% |
| EPS Diluted | -112.99% | -322.19% | 96.05% | 96.12% | 112.16% |
| Normalized Diluted EPS | 64.09% | 79.55% | 89.53% | 89.36% | 82.13% |
| Average Basic Shares Outstanding | 59.21% | 122.73% | 251.62% | 583.95% | 845.04% |
| Average Diluted Shares Outstanding | 59.21% | 122.73% | 251.62% | 583.95% | 845.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |